Peter Weseley, MD
Retina Specialist · New York, NYNPI 1679505374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Novartis at 45.3% of the total. Reporting peaked in 2019 at $372 and has fallen 70.9% since, to $108 in 2025. That places this record below the midpoint for retina specialist clinicians in NY, where the typical reported total is $2,298.
Across 12 payments — averaging $66.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$360
- Alcon$233
- Apellis Pharmaceuticals, Inc.$119
- Oyster Point Pharma, Inc.$39
- Eyepoint US, Inc.$24
- Aerie Pharmaceuticals, Inc.$21
What the payments were for
- Food & beverage$795100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $360 |
| Alcon | 2 | $233 |
| Apellis Pharmaceuticals, Inc. | 1 | $119 |
| Oyster Point Pharma, Inc. | 2 | $39 |
| Eyepoint US, Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$795 in reported general payments places this provider in the 25th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 33 | $84,521 |
| RestasisCyclosporine | 27 | $26,987 |
| Prednisolone Acetate | 93 | $5,285 |
| Difluprednate | 40 | $5,170 |
| Bromfenac Sodium | 37 | $4,752 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $4,153 |
| Loteprednol Etabonate | 18 | $3,659 |
| Ketorolac Tromethamine | 78 | $2,187 |
| Latanoprost | 174 | $1,608 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 81 | $1,503 |
| Brimonidine Tartrate | 27 | $1,014 |
| Dorzolamide Hcl | 41 | $614 |
| Timolol Maleate | 19 | $348 |
| MoxifloxacinMoxifloxacin Hcl | 16 | $305 |
| ErythromycinErythromycin Base | 27 | $262 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in New York
- Szilard KissNew York$195K
- Donald D'amicoNew York$109K
- Gareth LemaNew York$11K
- Megan Ridley LaneNew York$11K
- Carl WilkinsNew York$9K
- Gennady LandaNew York$7K
- Joseph TsengNew York$6K
- Ben CohenNew York$5K
- Alan SheymanNew York$4K
- Steven AgemyNew York$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.